恒瑞医药，拟赴香港上市，保荐人可能包括花旗、摩根士丹利

瑞恩资本Ryanbe...11-08

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！外媒最新消息指，来自江苏连云港的内地医药巨头恒瑞医药(600276.SH)，正在准备于2025年赴香港IPO募资，选定花旗、摩根士丹利牵头统筹香港IPO，并拟募资约20亿美元。恒瑞医药曾在10月中传出有意香港IPO集资。恒瑞医药当时在上交所发公告，承认正研究境外融资，正处于前期工作，具体实施方式以及实施时间具有重大不确定性。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481811532?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-08 13:20","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2481811532","market":"sg","top_or_hot":-1,"title":"恒瑞医药，拟赴香港上市，保荐人可能包括花旗、摩根士丹利","media":"瑞恩资本Ryanbe...","content":"<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 外媒最新消息指，来自江苏连云港的内地医药巨头恒瑞医药(600276.SH)，正在准备于2025年赴香港IPO募资，选定花旗、摩根士丹利牵头统筹香港IPO，并拟募资约20亿美元。恒瑞医药曾在10月中传出有意香港IPO集资。恒瑞医药当时在上交所发公告，承认正研究境外融资，正处于前期工作，具体实施方式以及实施时间具有重大不确定性。...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药，拟赴香港上市，保荐人可能包括花旗、摩根士丹利</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药，拟赴香港上市，保荐人可能包括花旗、摩根士丹利\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 13:20 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml><strong>瑞恩资本Ryanbe...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 外媒最新消息指，来自江苏连云港的内地医药巨头恒瑞医药(600276.SH)，正在准备于2025年赴香港IPO募资，选定花旗、摩根士丹利牵头统筹香港IPO，并拟募资约20亿美元。恒瑞医药曾在10月中传出有意香港IPO集资。恒瑞医药当时在上交所发公告，承认正研究境外融资，正处于前期工作，具体实施方式以及实施时间具有重大不确定性。...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0098860793.USD","symbol_name":"FRANKLIN INCOME \"A\" INC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml","article_id":"2481811532","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-08/doc-incvisyn8794196.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481811532","pubTimestamp":1731043200,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"外媒最新消息指，来自江苏连云港的内地医药巨头恒瑞医药，正在准备于2025年赴香港IPO募资，选定花旗、摩根士丹利牵头统筹香港IPO，并拟募资约20亿美元。恒瑞医药曾在10月中传出有意香港IPO集资。恒瑞医药当时在上交所发公告，承认正研究境外融资，正处于前期工作，具体实施方式以及实施时间具有重大不确定性。截至午间收市，恒瑞医药每股报人民币48.51元，总市值约人民币3094.45亿元。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK0239":"医药制造","BK4207":"综合性银行","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK4581":"高盛持仓","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0183":"MSCI概念","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4504":"桥水持仓","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","BK0196":"行业龙头","LU0106831901.USD":"贝莱德世界金融基金A2","BK4127":"投资银行业与经纪业","BK0012":"证金概念","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK4516":"特朗普概念","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK0060":"抗癌","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0971096721.USD":"富达环球金融服务 A","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4585":"ETF&股票定投概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK0028":"国家队","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","BK4566":"资本集团","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4588":"碎股","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC"},"translate_title":"Hengrui Medicine plans to go public in Hong Kong, sponsors may include Citigroup and Morgan Stanley","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1},"content_text":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 外媒最新消息指，来自江苏连云港的内地医药巨头恒瑞医药(600276.SH)，正在准备于2025年赴香港IPO募资，选定花旗、摩根士丹利牵头统筹香港IPO，并拟募资约20亿美元。恒瑞医药曾在10月中传出有意香港IPO集资。恒瑞医药当时在上交所发公告，承认正研究境外融资，正处于前期工作，具体实施方式以及实施时间具有重大不确定性。恒瑞医药，成立于1970年，作为一家专注研发、生产及推广高品质药物的创新型国际化制药企业，聚焦抗肿瘤、代谢性疾病、自身免疫疾病、呼吸系统疾病、神经系统疾病等领域进行新药研发，是国内最具创新能力的制药龙头企业之一。其于2000年在上海证券交易所上市。截至午间收市，恒瑞医药每股报人民币48.51元，总市值约人民币3094.45亿元。版权声明：所有瑞恩资本Ryanben Capital的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则瑞恩将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。更多香港上市、美国上市等境外IPO资讯可供搜索、查阅，敬请浏览: www.ryanbencapital.com\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481811532"}